AntriaBio Inc  

(Public, OTCMKTS:ANTB)   Watch this stock  
Find more results for antb
-0.050 (-5.26%)
Delayed:   11:52AM EST
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.85 - 0.90
52 week 0.62 - 2.00
Open 0.89
Vol / Avg. 63,750.00/10,645.00
Mkt cap 35.01M
P/E     -
Div/yield     -
EPS -0.76
Shares 40.95M
Beta -0.57
Inst. own     -

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -196.10% -134.76%
Return on average equity -243.02% -234.59%
Employees 19 -
CDP Score - -


1450 Infinite Dr
LOUISVILLE, CO 80027-9440
United States - Map
+1-303-2222128 (Phone)
+1-302-6365454 (Fax)

Website links


AntriaBio, Inc. is a biopharmaceutical company. The Company develops sustained release injectable therapies. The Company's products include AB101 and AB301. The Company's lead product candidate, AB101, is a microsphere formulation of PEGylated human recombinant insulin, is being developed as an extended acting basal insulin intended for once-weekly subcutaneous injection, for use alone and in combination with bolus prandial insulin or oral glucose lowering therapies, to improve glycemic control in patients with Type 1 and Type 2 Diabetes Mellitus. It has conducted pre-clinical studies, including acute and sub-acute toxicity studies in two species, safety pharmacology, and mutagenicity/genotoxicity studies. Its product candidate, AB301, is a once-weekly injectable combination of a pegylated human glucagon-like peptide-1 (GLP-1) agonist and AB101, the Company's basal insulin lead product candidate. The Company is engaged in additional ongoing preclinical studies of AB301.

Officers and directors

Nevan C. Elam Chairman of the Board, President, Chief Executive Officer
Age: 47
Morgan Fields Chief Accounting Officer
Age: 34
Sankaram Mantripragada Ph.D. Chief Scientific Officer
Age: 55
Barry M. Sherman M.D. Director
David F. Welch Ph.D. Director
Age: 55
Hoyoung Huh Ph.D. Independent Director
Age: 46